PharmAust CEO's sayanora triggers stock plunge
Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.